跳到正文
openFDA 已分级药品召回执法报告·· 26 天前精选AI 评分64

FDA 执法报告 D-0045-2027:Ascend Laboratories 氨氯地平/奥美沙坦酯片因溶出度不合格被列为 II 类召回

FDA drug enforcement D-0045-2027: Ascend Laboratories, LLC — Out of specification due to dissolution.

AI 导读

FDA 执法报告 D-0045-2027 将 Ascend Laboratories, LLC 的氨氯地平/奥美沙坦酯片(10mg/40mg)召回列为 II 类,原因为溶出度不符合标准。

推荐理由

该条目为 openFDA 执法报告记录,显示氨氯地平/奥美沙坦酯片因溶出度不符合标准被列为 II 类召回,可核对批次与分销范围。

正文 · AI 翻译

FDA 药品召回执行报告 — D-0045-2027

报告发布日期:2026-10-28。这是执行报告的日期,不是召回启动日期。

范围:一条已分类的药品召回记录;event_id 可能对应多个产品。没有召回编号的未分类记录不在本数据流范围内。本记录不是新闻稿,也不是新的执法结论。

openFDA 数据集每周更新。报告状态不是实时召回状态,不得用于跟踪召回生命周期。以下其他日期保留其各自名称所对应的含义。

完整官方产品记录(包括 openFDA 统一标识符):

{

"address_1": "135 Us Highway 202 206 Ste 15",

"address_2": "",

"center_classification_date": "20261016",

"city": "Bedminster",

"classification": "Class II",

"code_info": "批号 25120696,有效期:2026年12月31日。",

"country": "United States",

"distribution_pattern": "美国全国范围",

"event_id": "100053",

"initial_firm_notification": "Letter",

"more_code_info": "",

"openfda": {

"application_number": [

"ANDA209042"

],

"brand_name": [

"AMLODIPINE AND OLMESARTAN MEDOXOMIL"

],

"generic_name": [

"AMLODIPINE AND OLMESARTAN MEDOXOMIL"

],

"is_original_packager": [

true

],

"manufacturer_name": [

"Ascend Laboratories, LLC"

],

"package_ndc": [

"67877-499-30",

"67877-499-90",

"67877-500-30",

"67877-500-90",

"67877-501-30",

"67877-501-90",

"67877-502-30",

"67877-502-90"

],

"product_ndc": [

"67877-499",

"67877-500",

"67877-501",

"67877-502"

],

"product_type": [

"HUMAN PRESCRIPTION DRUG"

],

"route": [

"ORAL"

],

"rxcui": [

"730861",

"730866",

"730869",

"730872"

],

"spl_id": [

"32238052-6c4c-4b29-a59e-524c819c69f1"

],

"spl_set_id": [

"c1204fbe-d086-43cf-bbaa-efec9cd0487c"

],

"substance_name": [

"AMLODIPINE BESYLATE",

"OLMESARTAN MEDOXOMIL"

],

"unii": [

"6M97XTV3HD",

"864V2Q084H"

]

},

"postal_code": "07921-2608",

"product_description": "苯磺酸氨氯地平与奥美沙坦酯片,10mg/40mg,30片装,处方药,生产商:Alkem Laboratories Ltd.,印度,经销商:Ascend Laboratories, LLC,Parsippany, NJ 07054,NDC 67877-502-30。",

"product_quantity": "11,424 瓶。",

"product_type": "Drugs",

"reason_for_recall": "溶出度不符合标准。",

"recall_initiation_date": "20261006",

"recall_number": "D-0045-2027",

"recalling_firm": "Ascend Laboratories, LLC",

"report_date": "20261028",

"state": "NJ",

"status": "Ongoing",

"voluntary_mandated": "Voluntary: Firm initiated"

}

来源:openFDA 已分级药品召回执法报告 · api.fda.gov